Expect higher ASP following China’s stimulus
Expect strong sales in 2023 driven by the US approval of zanubrutinib in CLL
Operation Aspides, or the Peril of Low Expectations in Yemen
1Q23 results beat and expect gradual recovery
China Auto Sector – Jun leading indicators: NIO weaker than expected
Net profit +3.5x YoY in 2022 but below expectations; Attractive yield of 20%
Expect solid 2023E earnings; Higher free float to boost valuation
1H23 Preview: expect weakness in-line; Back-end loaded in 2H23E
China Policy – Credit growth is expected to rebound in 2023
Expect an improving trend after a weak 1Q24